Sanofi Sa · EURONEXT:SAN
Sanofi Sa — Investor Day (December 2025)
29 slides from Sanofi Sa's investor day presentation, Dec 16, 2025
Slide 1: sanofi
sanofi
Slide 2: Year-end late-stage pipeline review
Year-end late-stage pipeline review December 16, 2025
Slide 3: Forward-looking statements
Forward-looking statements This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlyin
Slide 4: Building a skilled and thoughtful R&D leadership team
Building a skilled and thoughtful R&D leadership team Chris Corsico Helen Merianos Jean-François Toussaint Karin Wåhlander Kripa Ram Head of development Head of R&D strategy and Head of R&D Vaccines1 Head of translational Head of chemistry, New in 2025 portfolio management medicines manufacturing an
Slide 5: Leading indicators for an R&D-driven biopharma company
Leading indicators for an R&D-driven biopharma company Publications1 Patents High-reputation journals 109 Filed (US, EU, Japan, and China) 29 350 311 24 21 20 300 248 228 45 15 250 195 179 200 21 26 11 10 10 150 7 8 5 6 5 6 6 5 100 4 4 4 1 50 Cell NEJM Lancet Nature 0 2020 2021 2022 2023 2024 2021 2
Slide 6: 2025: three new medicines and vaccines approved
2025: three new medicines and vaccines approved Qfitlia Wayrilz Nuvaxovid First RNAi antithrombin in First BTK inhibitor in ITP First recombinant COVID-19 hemophilia A and B approved in the US and vaccine with full approval approved in the US and China under review in the EU1, in the US and the EU J
Slide 7: 2025: advancing the mid- and late-stage pipeline
2025: advancing the mid- and late-stage pipeline ? ? Sarclisa amlitelimab balinatunfib itepekimab amlitelimab efdoralprin alfa 212 Pb-dotamtate tolebrutinib subcutaneous showed benefits in achieved clinically met primary met primary and met all primary showed efficacy on did not meet met co-primary
Slide 8: Dupixent: three new advances in dermatology and respiratory
Dupixent: three new advances in dermatology and respiratory Bullous pemphigoid Chronic spontaneous urticaria Allergic fungal rhinosinusitis Benefit across relevant endpoints Successful regulatory process Positive LIBERTY-AIMS phase 3 study Patients achieving Patients with ≥4-point improvement in PP-
Slide 9: Dermatology: important progress expands in key indications
Dermatology: important progress expands in key indications amlitelimab (OX40L mAb) brivekimig (TNFaxOX40L Nanobody® ) AD: first phase 3 study met primary and key secondary endpoints HS: phase 2a study achieved primary objective Clinically meaningful improvement Placebo-adjusted vIGA-AD Clinically me
Slide 10: Respiratory: exploring new modalities to improve patient benefit
Respiratory: exploring new modalities to improve patient benefit amlitelimab (OX40L mAb) itepekimab (IL33 mAb) Asthma: exploratory phase 2 efficacy in difficult-to-treat subgroup COPD: mixed phase 3 results Adjusted annualized event rate of severe % AER reduction over 48 weeks compared AERIFY-1: sig
Slide 11: Respiratory: exploring the potential of lunsekimig dual targeting
Respiratory: exploring the potential of lunsekimig dual targeting lunsekimig (IL13xTSLP Nanobody® ) Additional, exploratory studies Asthma: efficacy signal observed in phase 1b Phase 2/3 studies in COPD patients Early data: rapid and significant 40.9 ppb reduction in FeNO levels (90% CI: -55.4 to -2
Slide 12: Other immunology: progress in new areas
Other immunology: progress in new areas balinatunfib (oral TNFR1 inhibitor) duvakitug (TL1A mAb) Exploratory phase 2 efficacy CD/UC: positive and encouraging phase 2b data presented at ECCO 2025 Phase 2 studies in psoriasis and rheumatoid Crohn’s disease ulcerative colitis arthritis (RA) both showed
Slide 13: Wayrilz: expanding in rare diseases
Wayrilz: expanding in rare diseases Now approved in Taking a potentially disease-modifying ITP in the US1 treatment beyond ITP ITP wAIHA IgG4-related disease • Under review • Orphan drug (US) Phase 2 study showed considerable reduction in disease flare and (EU, JP, CN) • Phase 3 NEW activity despite
Slide 14: Rare and oncology: building pipeline in select areas
Rare and oncology: building pipeline in select areas Blueprint efdoralprin alfa Leader in mast cell diseases AATD emphysema: phase 2 study met all primary and key secondary endpoints elenestinib • Potential next-generation D816V-mutated AAT recombinant protein with KIT inhibitor currently in a phase
Slide 15: Sarclisa: lifecycle delivered for patients
Sarclisa: lifecycle delivered for patients newly diagnosed MM relapsed, refractory MM Subcutaneous data Positive data across multiple regimens transplant-eligible transplant-ineligible ≥two prior lines ≥one line Sarclisa-Pd established non-inferiority in R/R MM in IRAKLIA phase 3 study +VRd +VRd +Pd
Slide 16: Neurology: addressing MS with two different targets
Neurology: addressing MS with two different targets tolebrutinib (BTK inhibitor) frexalimab (CD40L mAb) SPMS: phase 3 with disability benefit RMS: phase 2 study demonstrated combined • 31% delay in time to onset of 6-month CDP adaptative and innate immune regulation disability (HR 0.69; 95% CI, 0.55
Slide 17: Neurology: riliprubart potential to expand in neuroinflammation
Neurology: riliprubart potential to expand in neuroinflammation Open-label phase 2 study across different CIDP patients Inhibiting upstream the classical complement demonstrated encouraging and sustained efficacy pathway across inflammatory diseases Part A at Week 24 CIDP AMR Primary and all seconda
Slide 18: Vaccines: commitment to respiratory diseases
Vaccines: commitment to respiratory diseases From a legacy in influenza… to RSV1 and COVID-192… to further respiratory vaccines pneumococcal • 21-valent conjugate disease children3 • PCV21+ Discontinued after 80% 40+ RSV toddler futility analysis reduction in hospitalization countries RSV+HMPV • mRN
Slide 19: 2025: continued innovation in influenza vaccines
2025: continued innovation in influenza vaccines Fluzone HD/Efluelda Influenza+COVID-19 Influenza H5 pandemic mRNA Positive phase 1/2 results Positive phase 1/2 results FLUNITY-HD1: world’s largest effectiveness Fluzone HD+ Flublok+ 93% seroprotection across both age groups phase 4 study with 466k o
Slide 20: 2025: progress in other respiratory diseases, incl. RSV+HMPV
2025: progress in other respiratory diseases, incl. RSV+HMPV Monovalent RSV (mRNA) Bivalent RSV+HMPV (mRNA) Bivalent RSV+HMPV2 (Vicebio) High efficacy in phase 2 study High neutralizing HMPV antibody titers Strong RSV and HMPV immune responses in phase 1/2 study in phase 1 Efficacy in line with appr
Slide 21: Other developments: replenishing pipeline, technologies
Other developments: replenishing pipeline, technologies Seven new molecules added in phase 1 Licensing and acquisitions SAR448501 CD20 bispecific mAb inflammatory indication NEW Dren Bio acquisition SAR448851 TREM2 agonist Alzheimer’s disease NEW CD20-directed myeloid cell engager SAR446523 GPRC5D m
Slide 22: R&D digital plan aims at significant cycle time reduction
R&D digital plan aims at significant cycle time reduction Drug discovery and design Clinical, regulatory, and process development Approval and launch readiness pre-clinical dossier dossier research phase 1 phase 2 phase 3 development preparation registration approval industry median 10-15 years curr
Slide 23: Pipeline: key mid- and late-stage development projects
Pipeline: key mid- and late-stage development projects Immunology Rare diseases/Oncology Neurology Vaccines phase 3 AD approved ITP (US) under review SPMS amlitelimab Wayrilz tolebrutinib Fluzone HD phase 3 flu 50 years+ potential LCM potential LCM (US, EU) phase 2 asthma lunsekimig elenestinib phas
Slide 24: Pipeline: upcoming news flow
Pipeline: upcoming news flow amlitelimab – AD (full data) brivekimig – HS frexalimab – RMS Nexviazyme – IOPD Dupixent – CPUO riliprubart – CIDP lunsekimig – asthma venglustat – Fabry disease itepekimab – CRSwNP SP0202 – PCV SP0230 – meningitis* venglustat – GD3 Dupixent – LSC fitusiran – hemophilia
Slide 25: Summary
Summary R&D leadership Pipeline highlights Pipeline replenishment, 2026 and 2027 and organization Three new medicines business development, news flow Building a skilled and and vaccines in 2025: and digital thoughtful R&D leadership Qfitlia, Wayrilz, and Nuvaxovid regulatory team, and R&D organizati
Slide 26: Q&A session
Q&A session To ask a question By Zoom By phone Any problems? Click on the Raise and lower your Email us: Raise hand icon hand: dial *9 investor.relations@sanofi.com Check your audio device Unmute and mute is well connected your microphone: dial *6
Slide 27: Collaborations
Collaborations Ref Name Companies Dupixent itepekimab Regeneron Kevzara frexalimab ImmuNext SP0202 SK bioscience duvakitug Teva Pharmaceuticals SAR447873 RadioMedix, Orano Med ALTUVIIIO Swedish Orphan Biovitrum (Sobi) Beyfortus AstraZeneca Nuvaxovid Novavax aficamten Cytokinetics plozasiran Arrowhea
Slide 28: Abbreviations
Abbreviations AAT alpha-1-antitrypsine HD high-dose PCV pneumococcal conjugate vaccine AATD alpha-1-antitrypsine deficiency HiSCR hidradenitis suppurativa clinical response Pd pomalidomide + dexamethasone AAV adeno-associated virus HMPV human metapneumovirus PIV3 parainfluenza virus type 3 AD atopic
Slide 29: Slide 29